Physician profile
Sheryl S Ream
NPI 1811989551
$2,876.33
in general payments reported to CMS, 2019-2025
22 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $430 · 2021: $438 · 2022: $359 · 2023: $122 · 2024: $253 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.67 | 2021-2024 | |
| Glaxosmithkline, LLC. | $342.45 | 2019-2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $316.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $287.54 | 2019-2024 | |
| Novo Nordisk INC | $287.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $169.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $153.94 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $123.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $109.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $88.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.55 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Exact Sciences Corporation | $54.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Recordati_rare_diseases_inc. | $46.56 | 2021 | |
| Amarin Pharma, INC. | $38.17 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $26.88 | 2019 | |
| Astellas Pharma US INC | $24.36 | 2019 | |
| Nevro Corp. | $20.76 | 2022 | |
| Axsome Therapeutics, INC. | $19.96 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $16.28 | 2019 | |
| Merck Sharp & Dohme LLC | $16.22 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Circassia INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheryl Ream listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.